Loading
A phase 1/2 trial of AP203 in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer, run by AP Biosciences Inc., now recruiting.
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies is a phase 1/2 interventional study registered as NCT05473156 by AP Biosciences Inc., with 168 participants planned, started 2023-07-24 and due to reach its primary completion in 2026-12. Interventions recorded: AP203.
Shares AP Biosciences and the tag pipeline.
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Non-small-cell lung cancer and the tag pipeline.